Johnson & Johnson (NYSE:JNJ) Shares Down 0.8%

Johnson & Johnson (NYSE:JNJ) shares fell 0.8% during mid-day trading on Monday . The stock traded as low as $158.05 and last traded at $159.34. 1,393,253 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 7,306,865 shares. The stock had previously closed at $160.64.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on JNJ. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. HSBC upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price objective for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. TD Cowen decreased their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Finally, Bank of America cut their target price on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Stock Performance

The company has a market cap of $382.85 billion, a price-to-earnings ratio of 9.93, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. The firm has a 50-day simple moving average of $148.74 and a 200 day simple moving average of $153.12. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the previous year, the company posted $2.80 earnings per share. The firm’s revenue was up 4.3% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.12%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Innealta Capital LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $27,000. Christopher J. Hasenberg Inc purchased a new stake in shares of Johnson & Johnson in the first quarter valued at approximately $31,000. Keener Financial Planning LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $40,000. WFA Asset Management Corp boosted its stake in shares of Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares in the last quarter. Finally, MFA Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $43,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.